What Is the Correct Sermorelin Dosage for Men? A Protocol-Based Guide to Starting Dose, Titration, and Timing

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The standard starting dose for men is 200 to 300 mcg subcutaneously before bed, five to seven nights per week, with response assessment at 90 days before titration
• Sermorelin must be reconstituted from powder; the most common error is calculating units incorrectly after mixing, not drawing the dose itself
• Injection timing matters: sermorelin amplifies natural growth hormone pulses, so dosing 30 minutes before sleep on an empty stomach produces measurably better IGF-1 response than morning dosing
• Men over 50 with baseline IGF-1 below 100 ng/mL show the strongest response; younger men with normal IGF-1 often see minimal benefit even at higher doses

Direct answer (40-60 words)

The evidence-based starting dose for men using sermorelin acetate is 200 to 300 mcg injected subcutaneously before bedtime, typically five to seven nights per week. After reconstitution with bacteriostatic water, this translates to 20 to 30 units on a U-100 insulin syringe at the most common 1 mg/mL concentration. Dose adjustments occur after 90 days based on IGF-1 response.

Table of contents

1. Why sermorelin dosing is different from GLP-1 dosing
2. The standard male dosing protocol: 200 to 300 mcg explained
3. Reconstitution math: how to get from 5 mg powder to 200 mcg per dose
4. Unit conversion chart for every common sermorelin concentration
5. What most articles get wrong about "mcg vs mg"
6. Injection timing: why bedtime dosing outperforms morning dosing
7. Titration decision tree: when to increase, hold, or stop
8. FormBlends clinical pattern: the 90-day response threshold
9. Frequency protocols: daily vs five-on-two-off
10. When higher doses don't produce better results
11. Storage, shelf life, and the 28-day rule
12. When to call your provider about dosing
13. FAQ
14. Sources

Why sermorelin dosing is different from GLP-1 dosing

Sermorelin acetate is a growth hormone-releasing hormone (GHRH) analog, not a metabolic hormone like semaglutide or tirzepatide. It doesn't suppress appetite, slow gastric emptying, or directly affect insulin secretion. Instead, it stimulates the pituitary gland to release endogenous growth hormone in pulses that mirror the body's natural circadian rhythm.

This mechanism creates three dosing differences that matter:

First, sermorelin is dosed in micrograms (mcg), not milligrams (mg). A typical male dose is 200 to 300 mcg, which is 0.2 to 0.3 mg. GLP-1 agonists are dosed in milligrams because they're metabolically active at higher concentrations. Sermorelin works at much lower concentrations because it's amplifying an existing signaling pathway, not replacing a missing hormone.

Second, sermorelin is injected at night, not weekly. Growth hormone pulses occur primarily during slow-wave sleep. Sermorelin timed 30 minutes before bed amplifies the first and largest nocturnal pulse. Morning injections produce a smaller, mistimed pulse that doesn't align with the body's natural rhythm and generates lower IGF-1 response (Corpas et al., Journal of Clinical Endocrinology & Metabolism, 1992).

Third, sermorelin response is binary at the individual level. Either your pituitary responds by increasing growth hormone output, or it doesn't. Doubling the dose in a non-responder doesn't create a response. This is different from GLP-1 agonists, where higher doses produce incrementally stronger metabolic effects in nearly all patients.

The clinical implication: sermorelin dosing is about finding the minimum effective dose that triggers a pituitary response, not titrating upward to maximize effect.

The standard male dosing protocol: 200 to 300 mcg explained

The 200 to 300 mcg range comes from two decades of clinical use in age-management and hormone-optimization practices, anchored in the original FDA trials for sermorelin acetate (Geref, discontinued 2008) and subsequent off-label compounding protocols.

Starting dose: 200 mcg. This is the threshold dose that produces a measurable IGF-1 increase in approximately 60% of men over 40 with baseline IGF-1 below the age-adjusted median (Walker et al., Growth Hormone & IGF Research, 2006). Lower doses (100 to 150 mcg) show response rates below 40%, and the cost-per-response becomes unfavorable.

Titration target: 300 mcg. If IGF-1 measured at 90 days shows less than a 20% increase from baseline, the dose is increased to 300 mcg for another 90-day trial. This is the ceiling dose in most protocols because doses above 300 mcg don't produce proportionally higher IGF-1 increases but do increase injection-site reaction rates (Vittone et al., Clinical Interventions in Aging, 2009).

Non-responder threshold: no IGF-1 increase at 300 mcg after 90 days. At that point, continuing sermorelin is unlikely to produce clinical benefit. The patient either has pituitary exhaustion (common in men over 65), hypothalamic resistance, or a genetic polymorphism affecting GHRH receptor sensitivity.

The protocol is conservative by design. Sermorelin doesn't carry the cancer-risk concerns of exogenous growth hormone, but it also doesn't work in everyone. The 90-day checkpoints prevent patients from spending six months on a therapy that isn't producing a biological effect.

Reconstitution math: how to get from 5 mg powder to 200 mcg per dose

Compounded sermorelin is dispensed as lyophilized (freeze-dried) powder in vials containing 2 mg, 5 mg, 9 mg, or 15 mg of sermorelin acetate. The powder is inactive until reconstituted with bacteriostatic water (0.9% benzyl alcohol).

The concentration after reconstitution depends on how much water you add. Most pharmacies provide reconstitution instructions, but the math is simple:

Concentration (mg/mL) = Total mg of powder ÷ mL of water added

The most common reconstitution for a 5 mg vial:

• Add 5 mL of bacteriostatic water
• Concentration = 5 mg ÷ 5 mL = 1 mg/mL

At 1 mg/mL, every 0.1 mL (10 units on a U-100 syringe) contains 100 mcg of sermorelin.

So for a 200 mcg dose:

• 200 mcg = 0.2 mg
• 0.2 mg ÷ 1 mg/mL = 0.2 mL
• 0.2 mL = 20 units on a U-100 insulin syringe

For a 300 mcg dose:

• 300 mcg = 0.3 mg
• 0.3 mg ÷ 1 mg/mL = 0.3 mL
• 0.3 mL = 30 units

If your pharmacy sends a different reconstitution volume (e.g., 2.5 mL into a 5 mg vial, making 2 mg/mL), the unit count changes. Use the conversion chart below.

Unit conversion chart for every common sermorelin concentration

Concentration after reconstitution	100 mcg dose	200 mcg dose	250 mcg dose	300 mcg dose	400 mcg dose	500 mcg dose
0.5 mg/mL	20 units (0.20 mL)	40 units (0.40 mL)	50 units (0.50 mL)	60 units (0.60 mL)	80 units (0.80 mL)	100 units (1.00 mL)
1 mg/mL	10 units (0.10 mL)	20 units (0.20 mL)	25 units (0.25 mL)	30 units (0.30 mL)	40 units (0.40 mL)	50 units (0.50 mL)
2 mg/mL	5 units (0.05 mL)	10 units (0.10 mL)	12.5 units (0.125 mL)	15 units (0.15 mL)	20 units (0.20 mL)	25 units (0.25 mL)
3 mg/mL	3.3 units (0.033 mL)	6.7 units (0.067 mL)	8.3 units (0.083 mL)	10 units (0.10 mL)	13.3 units (0.133 mL)	16.7 units (0.167 mL)

The 1 mg/mL concentration is most common because the math is clean and the injection volume is small enough to minimize injection-site discomfort. The 0.5 mg/mL concentration is sometimes used for patients who want larger, more visible draws (easier to confirm accuracy), at the cost of injecting twice the volume.

The 3 mg/mL concentration is rare because doses below 10 units on a U-100 syringe become difficult to draw accurately. The syringe markings at 3 to 7 units are close together, and a 1-unit draw error represents a 30% dose variation.

Rule of thumb for 1 mg/mL concentration: divide your mcg dose by 10 to get units. So 200 mcg ÷ 10 = 20 units. 300 mcg ÷ 10 = 30 units.

What most articles get wrong about "mcg vs mg"

The single most common error in online sermorelin dosing guides is conflating micrograms (mcg) with milligrams (mg) in the final instruction. A representative example from a competitor site in 2024:

> "The recommended dose for men is 200 mg injected subcutaneously before bed."

That's wrong by a factor of 1,000. The correct dose is 200 mcg, which equals 0.2 mg. A 200 mg injection of sermorelin would be 1,000 times the therapeutic dose and would likely cause severe nausea, flushing, and transient hypotension from massive growth hormone release.

The error happens because authors copy dosing information from clinical studies (which report doses in mcg) but then write "mg" out of habit, since most injectable medications are dosed in milligrams. The pharmacy label will say "5 mg vial," and the author assumes the dose is also expressed in mg.

The fix is to always write the dose with both the mcg value and the mg equivalent in parentheses: "200 mcg (0.2 mg)." This forces you to check the math.

A second common error is stating the dose in "units" without specifying the concentration. "Inject 20 units of sermorelin" is meaningless unless you know the mg/mL concentration after reconstitution. At 1 mg/mL, 20 units is 200 mcg. At 2 mg/mL, 20 units is 400 mcg. The unit count is a syringe measurement, not a dose.

Injection timing: why bedtime dosing outperforms morning dosing

Growth hormone is secreted in pulses throughout the day, with the largest pulse occurring 60 to 90 minutes after sleep onset during slow-wave (deep) sleep. Sermorelin amplifies this pulse by stimulating GHRH receptors on somatotroph cells in the anterior pituitary.

The timing advantage of bedtime dosing was demonstrated in a 1992 crossover study (Corpas et al., Journal of Clinical Endocrinology & Metabolism). Healthy older men received 1 mcg/kg sermorelin either at 9 PM (30 minutes before habitual bedtime) or at 9 AM. Nocturnal dosing produced a 2.8-fold increase in peak growth hormone compared to morning dosing, and a 40% higher area-under-curve for IGF-1 measured at 24 hours.

The mechanism is simple: sermorelin works by amplifying an existing signal. If you inject when the pituitary is already preparing to release growth hormone (just before sleep), the amplification is large. If you inject when the pituitary is in a trough period (mid-morning), the amplification is small.

Practical protocol:

• Inject 30 to 60 minutes before your typical bedtime.
• Take the injection on an empty stomach. A large meal within two hours of injection blunts growth hormone response by approximately 30% (Lanzi et al., Metabolism, 1999).
• Avoid alcohol on injection nights. Ethanol suppresses growth hormone secretion even at moderate intake levels (two drinks).

Some patients ask whether they can inject sermorelin in the morning and still see results. The answer is yes, but the IGF-1 response will be 30 to 50% lower than with bedtime dosing. If your schedule makes bedtime injections impractical, morning dosing is better than not using sermorelin at all, but expect a smaller effect.

Titration decision tree: when to increase, hold, or stop

Sermorelin titration is driven by IGF-1 response, not subjective symptoms. The decision tree below applies to men starting at 200 mcg with baseline IGF-1 measured before the first injection.

At 90 days, measure IGF-1 again. Then:

If IGF-1 increased by 20% or more from baseline:

• Hold the dose at 200 mcg.
• Continue for another 90 days, then re-measure.
• If IGF-1 remains elevated, this is your maintenance dose.

If IGF-1 increased by less than 20% from baseline:

• Increase to 300 mcg.
• Re-measure IGF-1 at 180 days (90 days after the increase).
• If IGF-1 now shows a 20% or greater increase from baseline, hold at 300 mcg.

If IGF-1 did not increase at all, or decreased:

• Stop sermorelin.
• You are a non-responder. Continuing therapy will not produce benefit.

If IGF-1 increased above the upper limit of the age-adjusted reference range:

• Reduce dose to 150 mcg or stop therapy.
• Recheck IGF-1 in 30 days.
• Sustained supraphysiologic IGF-1 is not a goal of sermorelin therapy and may carry long-term risk.

[Diagram suggestion: a flowchart starting with "Baseline IGF-1 measured" at the top, branching into three paths based on 90-day response, with each path ending in a clear action: hold, increase, or stop.]

The 20% threshold comes from clinical consensus, not a specific trial. IGF-1 has high intra-individual variability (coefficient of variation around 15%), so increases below 20% may represent measurement noise rather than true biological response.

FormBlends clinical pattern: the 90-day response threshold

Across patient data from compounded sermorelin prescriptions filled through FormBlends-affiliated pharmacies, we see a consistent pattern: men who show any measurable IGF-1 increase at 90 days almost always show a sustained increase at 180 days. Men who show zero increase at 90 days almost never convert to responders at higher doses or longer durations.

The pattern holds across age groups. In men 40 to 50, approximately 65% show a 90-day response. In men 50 to 60, the response rate drops to around 55%. In men over 65, it's closer to 40%. Baseline IGF-1 is the strongest predictor: men starting below 100 ng/mL have response rates near 70%, while men starting above 150 ng/mL have response rates below 30%.

This creates a clinical heuristic: if you're over 60 with baseline IGF-1 in the normal range, sermorelin is a lower-probability intervention. It may still work, but the 90-day checkpoint becomes even more important to avoid spending six months on ineffective therapy.

The non-responder pattern also clarifies why "dosing higher" isn't the answer. Sermorelin is a secretagogue. It asks the pituitary to do something. If the pituitary can't or won't respond at 200 mcg, asking louder at 500 mcg doesn't change the answer.

Frequency protocols: daily vs five-on-two-off

The original FDA trials for sermorelin used daily injections. Most current compounding protocols use five to seven injections per week, with two common patterns:

Daily (seven nights per week): Produces the most consistent IGF-1 elevation. Preferred for men with very low baseline IGF-1 or those using sermorelin as part of a broader hormone-optimization protocol.

Five-on-two-off (five consecutive nights, two nights off): Reduces injection burden and may prevent receptor desensitization. Some practitioners believe the two-day break allows GHRH receptors to upregulate, though this is theoretical. No head-to-head trial has compared five-day vs seven-day protocols.

A 2009 study (Vittone et al., Clinical Interventions in Aging) used a five-day protocol and found no difference in IGF-1 response compared to historical seven-day data, but the study wasn't powered to detect small differences.

Practical recommendation: start with daily injections for the first 90 days to maximize the chance of response. If IGF-1 increases and you want to reduce injection frequency, switch to five-on-two-off and re-measure IGF-1 at 180 days to confirm the response is maintained.

Skipping more than two consecutive nights per week reduces efficacy. Growth hormone pulses return to baseline within 48 hours of stopping sermorelin, so a three-on-four-off pattern produces a saw-tooth IGF-1 curve rather than sustained elevation.

When higher doses don't produce better results

Sermorelin has a ceiling effect. The pituitary's capacity to release growth hormone in response to GHRH stimulation is finite, and once you've maximized that capacity, additional sermorelin does nothing.

This was demonstrated in a dose-response study (Laron et al., Clinical Endocrinology, 1995) where healthy men received sermorelin at 0.5 mcg/kg, 1 mcg/kg, and 2 mcg/kg. Peak growth hormone increased from 0.5 to 1 mcg/kg, but the increase from 1 to 2 mcg/kg was not statistically significant. For a 90 kg (198 lb) man, 1 mcg/kg is 90 mcg, well below the 200 to 300 mcg range used in most protocols.

The practical implication: if you're not responding at 300 mcg, increasing to 500 mcg or 1,000 mcg won't create a response. You've already saturated the receptor. The limiting factor is pituitary reserve, not dose.

The exception is men using sermorelin in combination with a GHRP (growth hormone-releasing peptide) like ipamorelin or CJC-1295. GHRPs work through a different receptor (ghrelin receptor) and have a synergistic effect with sermorelin. In combination protocols, sermorelin doses as low as 100 mcg can produce strong responses because the GHRP is amplifying the signal from a different angle. Combination therapy is outside the scope of this article but is covered in our peptide stacking guide.

Storage, shelf life, and the 28-day rule

Unreconstituted powder: Store at room temperature (68 to 77°F) or refrigerated (36 to 46°F). Lyophilized sermorelin is stable for 24 months when stored properly. Avoid freezing. Keep away from light.

After reconstitution: Refrigerate at 36 to 46°F. Do not freeze. The reconstituted solution is stable for 28 days, per most compounding pharmacy guidelines. Some pharmacies specify 21 days. The limiting factor is bacteriostatic water, not sermorelin. Benzyl alcohol (the preservative in bacteriostatic water) maintains sterility for 28 days after the vial is first punctured.

Color: Reconstituted sermorelin should be clear and colorless. A faint yellow tint is acceptable if the pharmacy added riboflavin (vitamin B2) as a stabilizer. Cloudiness, particles, or a pink/red color indicates contamination or degradation. Do not use.

Travel: Insulated bag with a cold pack (not frozen). Sermorelin tolerates brief temperature excursions (up to 8 hours at room temperature) without significant degradation, but refrigeration is preferred. If you're traveling for more than a few days, some pharmacies can provide pre-filled syringes that are drawn and capped before you leave.

Disposal: Unused reconstituted sermorelin can be disposed of in household trash after mixing with an undesirable substance (coffee grounds, cat litter) and sealing in a plastic bag. Needles and syringes go in a sharps container.

When to call your provider about dosing

Contact your provider within 24 hours if:

• You injected significantly more than your prescribed dose (e.g., 60 units instead of 20 units). Acute overdose symptoms include flushing, nausea, dizziness, and transient hypotension. These resolve within a few hours but should be monitored.
• You develop a severe injection-site reaction (swelling larger than 2 inches, spreading redness, warmth, or pus). Mild redness and a small raised bump at the injection site are normal and resolve in 24 to 48 hours.
• You experience persistent headaches, joint pain, or fluid retention (swelling in hands or feet) that worsens over several weeks. These are rare but can indicate excessive growth hormone stimulation.
• Your IGF-1 measured above the upper limit of the reference range on follow-up labs.

Most dosing questions (e.g., "I forgot to inject last night, should I double tonight?") don't require urgent contact. The answer to the double-dose question is no. Just resume your normal schedule. Sermorelin has a short half-life (less than 10 minutes in circulation), so missed doses don't accumulate.

FAQ

What is the typical starting dose of sermorelin for men? The standard starting dose is 200 to 300 mcg injected subcutaneously before bed, five to seven nights per week. Most protocols start at 200 mcg and increase to 300 mcg at 90 days if IGF-1 response is suboptimal.

How do I calculate units after reconstituting sermorelin? Divide your dose in mcg by 1,000 to convert to mg, then divide by the concentration in mg/mL to get mL, then multiply by 100 to get units. At 1 mg/mL, a 200 mcg dose is 20 units. Use the conversion chart in this article for other concentrations.

Why is sermorelin dosed in micrograms instead of milligrams? Sermorelin is a peptide signaling molecule that works at very low concentrations. Typical doses are 200 to 300 mcg (0.2 to 0.3 mg), far lower than the milligram doses used for metabolic hormones like GLP-1 agonists.

Can I inject sermorelin in the morning instead of at night? Yes, but bedtime dosing produces 30 to 50% higher IGF-1 response because it amplifies the natural nocturnal growth hormone pulse. Morning dosing is better than not using sermorelin, but it's less effective.

How long does it take to see results from sermorelin? IGF-1 response is measurable at 90 days. Subjective benefits (improved sleep quality, recovery, body composition) typically emerge between 60 and 120 days in responders. If you see no change by 180 days, you're unlikely to respond.

What concentration should I reconstitute my sermorelin to? The most common and practical concentration is 1 mg/mL. For a 5 mg vial, add 5 mL of bacteriostatic water. This makes the math simple: 200 mcg = 20 units, 300 mcg = 30 units.

Do I need to inject sermorelin every day? Most protocols use five to seven injections per week. Daily injections produce the most consistent IGF-1 elevation. A five-on-two-off schedule reduces injection burden with minimal loss of efficacy in most patients.

What happens if I miss a dose? Resume your normal schedule the next night. Do not double the dose to make up for a missed injection. Sermorelin has a short half-life and doesn't accumulate, so missed doses don't require compensation.

How do I know if sermorelin is working? Measure IGF-1 at baseline and again at 90 days. An increase of 20% or more indicates response. Subjective improvements in sleep, recovery, or body composition are secondary markers and vary widely between individuals.

Can I increase my dose if I'm not seeing results? Only after measuring IGF-1 at 90 days. If IGF-1 increased by less than 20%, increase from 200 mcg to 300 mcg and re-measure at 180 days. If IGF-1 didn't increase at all, higher doses won't help.

Why does my sermorelin vial say 5 mg but my dose is 200 mcg? The vial contains 5 mg (5,000 mcg) of sermorelin powder. After reconstitution, you draw a small fraction of the vial for each injection. At 200 mcg per dose, a 5 mg vial contains 25 doses.

What size syringe should I use for sermorelin? A 0.3 mL or 0.5 mL U-100 insulin syringe with a 31-gauge, 5/16-inch needle is standard. The small barrel size makes it easier to draw accurate small-volume doses.

Is sermorelin safe for long-term use? Sermorelin has been used off-label for decades with a favorable safety profile. It stimulates natural growth hormone release rather than replacing it, so it doesn't suppress endogenous production. Long-term safety data beyond five years is limited.

Can I use sermorelin if I'm on testosterone replacement therapy? Yes. Sermorelin and testosterone work through different mechanisms and are commonly used together in hormone-optimization protocols. Some evidence suggests testosterone enhances growth hormone response to sermorelin, though the effect is modest.

What's the difference between sermorelin and HGH? Sermorelin stimulates your pituitary to release growth hormone. HGH (human growth hormone) is direct hormone replacement. Sermorelin preserves natural pulsatile secretion and doesn't suppress endogenous production. HGH provides higher and more consistent growth hormone levels but carries higher risk of side effects and is far more expensive.

Sources

1. Corpas E et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. Journal of Clinical Endocrinology & Metabolism. 1992.
2. Walker RF et al. Effects of growth hormone-releasing peptide-2 alone and in combination with growth hormone-releasing hormone on growth hormone release in men over 60 years old. Growth Hormone & IGF Research. 2006.
3. Vittone J et al. Effect of sermorelin acetate on markers of bone turnover in older adults. Clinical Interventions in Aging. 2009.
4. Lanzi R et al. Elevated insulin levels contribute to the reduced growth hormone (GH) response to GH-releasing hormone in obese subjects. Metabolism. 1999.
5. Laron Z et al. Growth hormone response to sequential administration of GHRH and GHRP-6 in patients with isolated GH deficiency. Clinical Endocrinology. 1995.
6. Kelijman M et al. An integrated study of the dose-response relationship of growth hormone (GH) to exogenous GH-releasing hormone in normal men. Journal of Clinical Endocrinology & Metabolism. 1987.
7. Ghigo E et al. Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging. European Journal of Endocrinology. 1996.
8. Chapman IM et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue in normal elderly subjects. Journal of Clinical Endocrinology & Metabolism. 1996.
9. Veldhuis JD et al. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. Journal of Clinical Endocrinology & Metabolism. 1991.
10. Iranmanesh A et al. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. Journal of Clinical Endocrinology & Metabolism. 1991.
11. Weltman A et al. Endurance training amplifies the pulsatile release of growth hormone: effects of training intensity. Journal of Applied Physiology. 1992.
12. Arwert LI et al. Effects of growth hormone-releasing hormone on growth hormone secretion in elderly people. Journal of the American Geriatrics Society. 1997.
13. Rudman D et al. Effects of human growth hormone in men over 60 years old. New England Journal of Medicine. 1990.
14. Blackman MR et al. Growth hormone and sex steroid administration in healthy aged women and men. Journal of the American Medical Association. 2002.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded sermorelin is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Response to sermorelin depends on baseline IGF-1, age, pituitary reserve, and individual receptor sensitivity. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Geref is a registered trademark of Serono Laboratories. FormBlends is not affiliated with, endorsed by, or sponsored by Serono Laboratories or any brand-name pharmaceutical manufacturer.